Migdal Insurance & Financial Holdings Ltd. Krystal Biotech, Inc. Transaction History

Migdal Insurance & Financial Holdings Ltd.

$6.18 Billion
Q3 2024

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 04, 2021	SELL	$62.14 - $81.82 $785,449 - $1.03 Million	-12,640 Closed	0 $0
Q1 2021 May 04, 2021	BUY	$59.42 - $85.46 $466,090 - $670,348	7,844 Added 163.55%	12,640 $974,000
Q4 2020 Feb 08, 2021	BUY	$40.64 - $61.38 $194,909 - $294,378	4,796 New	4,796 $288,000

Others Institutions Holding KRYS

# of Institutions

310

Shares Held

24.3M

Call Options Held

483K

Put Options Held

364K

Black Rock Inc. New York, NY

3.95M
Shares

$626 Million
0.02% of portfolio
Vanguard Group Inc Valley Forge, PA

2.85M
Shares

$452 Million
0.01% of portfolio
Avoro Capital Advisors LLC New York, NY

2.62M
Shares

$416 Million
7.18% of portfolio
State Street Corp Boston, MA

1.45M
Shares

$230 Million
0.01% of portfolio
Frazier Life Sciences Management, L.P. Menlo Park, CA

988K
Shares

$157 Million
9.67% of portfolio

View Full List

About Krystal Biotech, Inc.

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $4.07B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

More about KRYS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Migdal Insurance & Financial Holdings Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Migdal Insurance & Financial Holdings Ltd. with notifications on news.

Account